CoronaryAtlas logo
CoronaryAtlas
Lipopolysaccharide-Binding Protein
Pathway / Off-pathway / systemic markers

Lipopolysaccharide-Binding Protein

LBPprotein

LBP facilitates innate immune responses and systemic inflammation associated with acute MI but acts on a distinct inflammatory axis.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleAcute-phase response and inflammatory progression marker; systemic rather than plaque-specific.
Also acts inCoagulation / thrombus, Vascular inflammation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000129988

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
47
C — confounder / Type-II
91
A — assay feasibility
68
E — evidence strength
33
T1DI (composite)
6
Specificity differential (R−C)-44.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(5)

Clinical trials(1)